Checklist: Closer To A Cure

Eli Lilly is putting the brakes on metastatic breast cancer.
Posted on Jul 20, 2021 | 06:00am
Brought to you by Watch

It is estimated that roughly 155,000 Americans are currently living with metastatic breast cancer, meaning breast cancer that has spread to other parts of the body such as the bones, lungs, liver, or brain. Representing about 70 percent of cases, the most common form of metastatic breast cancer is known as HR+/HER2- (hormone receptor positive/human epidermal growth-factor receptor 2 negative), and for those afflicted, medication Verzenio by Eli Lilly may offer new hope.

Used in conjunction with other therapies or alone, depending on a patient’s history, Verzenio is known as a CDK4 & 6 inhibitor—meaning it impedes over-activity of the cell growing-and-dividing proteins known as CDK4 & 6. By disrupting the process just as cells are about to grow and divide—which is how cancer spreads—Verzenio slows cancer cell growth, causing the cells to become inactive or even die. "In preclinical studies," says the drug’s maker, "continuous exposure to Verzenio put the brakes on CDK4 & 6 proteins, which delayed cancer cells from growing and dividing." Verzenio is the first and only oral tablet of its kind that can be taken twice daily.

Talk to your doctor to see Verzenio is right for you. For product information, prescribing information, medication guide, and possible side effects, visit verzenio.com.

Photo Credit: Westend61/Getty Images